Anti-HIV-1 activity, protease inhibition and safety profile of extracts prepared from Rhus parviflora

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Modi, Manoj ^a   Nutan, ^a   Pancholi, Boskey ^a   Kulshrestha, Shweta ^b   Rawat, Ajay Kumar Singh ^b   Malhotra, Swadesh ^b   Gupta, Satish Kumar ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b CSIR NATIONAL BOTANICAL RESEARCH INSTITUTE   (India)

Author keywords

Anti HIV 1 activity; Cytotoxicity; HIV 1 protease; Lactobacilli; Pro inflammatory cytokines; Rhus parviflora; Vaginal keratinocytes

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTERLEUKIN 1BETA; INTERLEUKIN 8; PLANT EXTRACT; PROTEINASE; RHUS PARVIFLORA EXTRACT; RNA DIRECTED DNA POLYMERASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; KERATINOCYTE; LACTOBACILLUS CASEI; LACTOBACILLUS FERMENTUM; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLANT LEAF; POISON IVY; PROTEINASE INHIBITION; REPORTER GENE; RHUS PARVIFLORA; VIRUS INHIBITION; VIRUS LOAD;

CACO-2 CELLS; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PLANT EXTRACTS; PLANT LEAVES; PROTEASE INHIBITORS; RHUS;

EID: 84879831977     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-158     Document Type: Article

References (40)

1. WHO, UNICEF and UNAIDS UNAIDS/WHO AIDS epidemic update November 2011 http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf, WHO, UNICEF and UNAIDS.
2. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Panel on clinical practices for treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002, 137:381-433. 10.7326/0003-4819-137-5_Part_2-200209031-00001, 12617573.
3. Hofman P, Nelson AM. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Curr Med Chem 2006, 13:3121-3132. 10.2174/092986706778742891, 17168701.
4. Este JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010, 85:25-33. 10.1016/j.antiviral.2009.10.007, 20018390.
5. Lange J. Triple combinations: present and future. J AIDS Hum Retrovirol 1995, 10(Suppl 1):77-82.
6. Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D, Pediatric AIDS Clinical Trials Group 381 Study Team Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial non-suppressive highly active antiretroviral therapy. AIDS Patient Care STDS 2008, 22:545-552. 10.1089/apc.2007.0200, 2929158, 18479228, Pediatric AIDS Clinical Trials Group 381 Study Team.
7. Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, Wells K, Wenner CA, Standish LJ. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res 2000, 14:333-338. 10.1002/1099-1573(200008)14:5<333::AID-PTR584>3.0.CO;2-D, 10925397.
8. Hammar L, Hirsch I, Machado AA, De Mareuil J, Baillon JG, Bolmont C, Chermann JC. Lectin-mediated effects on HIV type 1 infection in vitro. AIDS Res Hum Retroviruses 1995, 11:87-95. 10.1089/aid.1995.11.87, 7734200.
9. Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 1997, 60:884-888. 10.1021/np9700275, 9322359.
10. Otake T, Mori H, Morimoto M, Ueba N, Sutardjo S, Kusumoto IT, Hattori M, Namba T. Screening of Indonesian plant extracts for anti-human immunodeficiency virus type I (HIV-I) activity. Phytother Res 1995, 9:6-10.
11. Wang RR, Gu Q, Yang LM, Chen JJ, Li SY, Zheng YT. Anti HIV-1 activities of extracts from the medicinal plant Rhus Chinensis. J Ethnopharmacol 2006, 105:269-273. 10.1016/j.jep.2005.11.008, 16368204.
12. Kim HJ, Woo ER, Shin CG, Park HK. A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J Nat Prod 1998, 61:145-148. 10.1021/np970171q, 9461665.
13. Ahn MJ, Kim CY, Lee JS, Kim TG, Kim SH, Lee CK, Lee BB, Shin GG, Huh H, Kim J. Inhibition of HIV-I integrase by galloyl glucose from Terminalia chebula and flavonol glycoside gallates from Euphorbia pekinensis. Planta Med 2002, 68:457-459. 10.1055/s-2002-32070, 12058327.
14. Nutan, Gupta SK. Microbicides: a new hope for HIV prevention. Indian J Med Res 2011, 134:939-949. 10.4103/0971-5916.92639, 3284102, 22310826.
15. Press JR, Shrestha KK, Sutton DA. Annotated checklist of the flowering plants of Nepal 2000, London and Central Department of Botany, Kathmandu: The Natural History Museum.
16. Shrestha S, Park JH, Lee DY, Cho JG, Cho S, Yang HJ, Yong HI, Yoon MS, Han DS, Baek NI. Rhus parviflora and its biflavonoid constituents, rhusflavone, induce sleep through the positive allosteric modulation of GABA (A)-benzodiazepine receptors. J Ethanopharmacol 2012, 142:213-220.
17. Bajracharya D. Nutritive values of Nepalese edible wild fruits. Z Lebensm Unters Forsch 1980, 171:363-366. 10.1007/BF01087135, 7445758.
18. Bhattarai NK. Folk herbal medicines of Makawanpur district, Nepal. International J Pharmacog 1991, 29:284-295.
19. Semwal DP, Saradhi PP, Kala CP, Sajwan BS. Medicinal plants used by local Vaidyas in Ukhimath block, Uttarakhand. Indian J Trad Knowledge 2010, 9:480-485.
20. Kumar M, Sheikh MA, Bussmann RW. Ethno medicinal and ecological status of plants in Garhwal Himalaya. India J Ethnobiol Ethnomed 2011, 7:32-45.
21. Joseph GVR, Sathe MV. Pharmacognostic studies on the leaves of " Tintidika' Rhus parviflora Roxb. J Drug Res Ayurveda Siddha 2007, 28:1-8.
22. Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, Corbeil J. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci USA 1997, 94:4653-4658. 10.1073/pnas.94.9.4653, 20779, 9114046.
23. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90:8392-8396. 10.1073/pnas.90.18.8392, 47362, 7690960.
24. Mosmann T. Rapid colorimteric assay for cellular growth and survival; application to proliferation and cytotoxicity assays. J Immun Methods 1983, 65:55-63.
25. Kumar M, Mitra D. Heat shock protein 40 is necessary for Human Immunodeficiency Virus-1 Nef-mediated enhancement of viral gene expression and replication. J Biol Chem 2005, 280:41-50.
26. Fichorova RN, Rheinwald JG, Anderson DJ. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical and vaginal epithelium that maintain expression of tissue specific differentiation proteins. Biol Reprod 1997, 57:847-855. 10.1095/biolreprod57.4.847, 9314589.
27. Clancy CJ, Nguyen MH. Comparison of a photometric method with standardized methods of antifungal susceptibility testing of yeasts. J Clinical Microbiol 1997, 35:2878-2882.
28. Malekinejad H, Tukmechi A, Ebrahimi H, Bazargani-Gilani B. One step forward to improve the latest method of antibacterial susceptibility testing of vitro-cultured bacteria: an implication for antibacterial efficacy of Enrofloxacine on Aeromonas hydrophila. World J Microbiol Biotech 2011, 27:147-151.
29. Kratz JM, Andrighetti-Fröhner CR, Kolling DJ, Leal PC, Cirne-Santos CC, Yunes RA, Nunes RJ, Trybala E, Bergström T, Frugulhetti IC, Barardi CR, Simões CM. Anti-HSV-1 and anti-HIV-1 activity of Gallic acid and pentyl gallate. Mem Inst Oswaldo Cruz 2008, 103:437-442. 10.1590/S0074-02762008000500005, 18797755.
30. Reutrakul V, Ningnuek N, Pohmakotr M, Yoosook C, Napaswad C, Kasisit J, Santisuk T, Tuchinda P. Anti HIV-1 flavonoid glycosides from Ochna integerrima. Planta Med 2007, 73:683-688. 10.1055/s-2007-981538, 17562490.
31. Gali Y, Arien KK, Praet M, Van den Bergh R, Temmerman M, Delezay O, Vanham G. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J Virol Methods 2010, 165:186-197. 10.1016/j.jviromet.2010.01.018, 20138087.
32. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect 2007, 13:657-664. 10.1111/j.1469-0691.2007.01688.x, 17633390.
33. Kempf C, Jentsch P, Barre-Sinoussi FB, Poirier B, Morgenthaler JJ, Morell A, Germann D. Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin. J Acquir Immune Defic Syndr 1991, 4:828-830.
34. Klebanoff SJ, Coombs RW. Virucidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991, 174:289-292. 10.1084/jem.174.1.289, 2118880, 1647436.
35. Alberto MR, Farias ME, Manca De Nadra MC. Effect of gallic acid and catechin on Lactobacillus hilgardii 5w growth and metabolism of organic compounds. J Agric Food Chem 2001, 49:4359-4363. 10.1021/jf0101915, 11559138.
36. Lee CH, Jenner AM, Low SC, Lee YK. Effect of tea phenolics and their aromatic fecal bacteria metabolites on intestinal micro biota. Res Microb 2006, 157:876-884.
37. Fichorova RN, Zhou F, Ratnam V, Atanassova V, Jiang S, Strick N, Neurath AR. Anti-human immunodeficiency virus type 1 microbicides cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob Agents Chemother 2005, 49:323-335. 10.1128/AAC.49.1.323-335.2005, 538889, 15616312.
38. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled clinical trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998, 339:504-510. 10.1056/NEJM199808203390803, 9709043.
39. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Kitchen VS. Safety study of nonoxynol-9 as a vaginal microbicides: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:327-331. 10.1097/00042560-199804010-00006, 9525433.
40. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004, 71:761-769. 10.1095/biolreprod.104.029603, 15128598.